Dimerix |
High $0.06 |
Low $0.06 |
Trades 18 |
Turnover $32,113 |
Volume 526,676 |
| 30 June 2023 at 3:59pm | ||||
|
Market Cap (14-Nov) $120,079,360 (1,050th) |
Close (30-Jun) $0.062 |
Volume (30-Jun) 526,676 |
Shortsold (9-Nov) 3,622 (0.00%) (625th) |
|
52w High $0.67 |
52w Low $0.158 |
P/E 10.78 |
EPS -0.05 |
Ethics Approval in Australia for Phase 3 COVID-19 Study
DXB released this announcement to the ASX on 23 December 2021, 9:16. The announcement is marked as price sensitive, and is 4 page(s) in length and 344.65kb in size.
You can view all announcements from DXB and see how they appear on a price chart on the announcements page.
At the date of this announcement, DXB was 0.025% short sold according to ASIC data. It was ranked the 583rd most shorted stock on the ASX. It remains ranked 625th as of the latest reported data (09 November 2026).
| Other Recent Announcements from DXB | |
|---|---|
| Application for quotation of securities - DXB | 29 June 2023, 9:01 |
| Application for quotation of securities - DXB | 29 June 2023, 9:00 |
| Application for quotation of securities - DXB | 29 June 2023, 8:59 |
| Ethics Approval in Australia for Phase 3 COVID-19 Study | 23 December 2021, 9:16 |
| Dimerix Receives Further MRFF Funding for DMX-200 | 22 December 2021, 9:38 |
| DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe | 16 December 2021, 12:12 |
| Pause in Trading | 16 December 2021, 10:02 |
If you were already registered, log in here.